Marcus Hompesch

7PUBLICATIONS
11CO-AUTHORS
GlycoconjugatesPharmacogenomicsMedical molecular engineering of nucleic acids and proteinsBehavioural epidemiologyCross-sectional analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 06, 2025
GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial.

Christine L N Bryant, Kevin Colbert, Marcus Hompesch

|Mar 08, 2024
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.

Pablo Lapuerta, Silvia Urbina, Jiaojuan He

|Jun 13, 2023
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities.

Wonjung Shin, Marcus Hompesch, JinHee Byeon

|Apr 07, 2022
A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer.

Geoffrey A Walford, Kelly E Duncan, Moises Hernandez

|Jan 19, 2022
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.

Richard E Pratley, Stephan Jacob, Seungjae Baek

|Jun 26, 2021
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.

Marcus Hompesch, Jahoon Kang, OakPil Han

Pageof 2

Frequent Collaborators

1 joint publications

Carine Beysen

1 joint publications

Richard E Pratley

1 joint publications

Moises Hernandez

1 joint publications

Pavan Vaddady